Michael G. Benatar

Michael G. Benatar

Neuromusculoskeletal Medicine | Neurology
1150 Northwest 14th Street
Miami, FL 33136

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 206 publications

Repairing the Amyotrophic Lateral Sclerosis Trial Credibility Gap.

Repairing the Amyotrophic Lateral Sclerosis Trial Credibility Gap.

Journal: Neurology
Published: September 02, 2026

TDP-43-Associated Neurodegenerative Disease Conceptualization and Integrated Staging: A Review.

TDP-43-Associated Neurodegenerative Disease Conceptualization and Integrated Staging: A Review.

Journal: JAMA neurology
Published: August 24, 2026

Management of Exacerbations and Rescue Therapy: A Prespecified Analysis of the Phase 3 Myasthenia Gravis Inebilizumab Randomized Clinical Trial.

Management of Exacerbations and Rescue Therapy: A Prespecified Analysis of the Phase 3 Myasthenia Gravis Inebilizumab Randomized Clinical Trial.

Journal: JAMA neurology
Published: August 10, 2026

ALSUntangled #84 - ivermectin.

ALSUntangled #84 - ivermectin.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: August 06, 2026

SOD1-lowering therapy for patients with wildtype SOD1-ALS: a case report.

SOD1-lowering therapy for patients with wildtype SOD1-ALS: a case report.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: July 22, 2026

Likelihood-based modeling of covariate-specific time-dependent receiver operating characteristic curves.

Likelihood-based modeling of covariate-specific time-dependent receiver operating characteristic curves.

Journal: Statistical methods in medical research
Published: May 20, 2026

CoCoRV-nf: a powerful and cost-effective tool for rare variant analysis leveraging external biobank sequence data identified new candidate predisposition genes in amyotrophic lateral sclerosis and neuroblastoma.

CoCoRV-nf: a powerful and cost-effective tool for rare variant analysis leveraging external biobank sequence data identified new candidate predisposition genes in amyotrophic lateral sclerosis and neuroblastoma.

Journal: Human molecular genetics
Published: March 14, 2026

ALS untangled #83: clenbuterol.

ALS untangled #83: clenbuterol.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: March 08, 2026

ALSUntangled #82: N-acetylcysteine.

ALSUntangled #82: N-acetylcysteine.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: March 04, 2026

Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis.

Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis.

Journal: JAMA neurology
Published: February 09, 2026

Predicting Phenoconversion to Clinically Manifest ALS: Results of a Large-Scale Proteomic Study.

Predicting Phenoconversion to Clinically Manifest ALS: Results of a Large-Scale Proteomic Study.

Journal: medRxiv : the preprint server for health sciences
Published: December 18, 2025

Longitudinal plasma proteomics predict phenoconversion to clinically manifest ALS.

Longitudinal plasma proteomics predict phenoconversion to clinically manifest ALS.

Journal: Nature medicine
Published: December 01, 2025
Showing 1-12 of 206

Last Updated: 09/26/2026